title: Co-endemicity of loiasis and onchocerciasis in the South West Province of Cameroon: implications for mass treatment with ivermectin.
abstract: Encephalopathy has been reported in Cameroon in individuals heavily infected with Loa loa microfilariae who were treated with ivermectin against onchocerciasis. Prior to the initiation of the community-directed treatment of onchocerciasis with ivermectin (CDTI) in the South West Province of Cameroon, an epidemiological survey of loiasis was conducted (in July 1998-July 1999) to ascertain the intensity of the disease. Thick blood films were made from 1228 blood samples collected during the day. Rapid epidemiological assessment (REA) of onchocerciasis was conducted among 614 individuals in the Upper Bayang area. Sixteen percent of the population examined were carriers of L. loa microfilariae. More males (20.1%) than females (12.4%) were infected. The community mean microfilaraemias of the different villages were low (< 1100 mf/mL). However, 1 person was found harbouring 174,000 mf/mL of blood and 1% of the study population (12) had microfilaraemia > 8100 mf/mL. Results of the REA of onchocerciasis show that 31.3% of the population investigated in the Upper Bayang area have this disease. These findings show that loiasis and onchocerciasis are co-endemic in the area, but the risk of developing encephalopathy after taking ivermectin is small.
authors.affiliation: Department of Life Sciences, University of Buea, P.O. Box 63, Buea, Cameroon.
authors.forename: M
authors.initials: M
authors.lastname: Esum
authors.forename: S
authors.initials: S
authors.lastname: Wanji
authors.forename: N
authors.initials: N
authors.lastname: Tendongfor
authors.forename: P
authors.initials: P
authors.lastname: Enyong
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D002163:Cameroon / Q000453:epidemiology; D002648:Child; D019353:Endemic Diseases; D005260:Female; D005369:Filaricides / Q000627:therapeutic use*; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D008118:Loiasis / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009855:Onchocerciasis / Q000188:drug therapy* / Q000453:epidemiology; D015995:Prevalence; D000091402:Prohibitins; D017678:Sex Distribution
chemical_list: D005369:Filaricides; C000717331:PHB2 protein, human; D000091402:Prohibitins; D007559:Ivermectin